With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has secured four cornerstone investors to purchase shares together worth $550 million, with total net proceeds from the global offering possibly reaching as high $2.46 billion.
You may also be interested in...
China Distributor Consolidation Heats Up: Sinopharm Looks To Raise $440 Million Ahead Of Shanghai Pharma IPO
SHANGHAI - China's largest drug distributor Sinopharm Group Co. Ltd. April 25 placed a secondary offering of roughly 138 million H shares in Hong Kong looking to raise HK$3.4 billion ($440 million) to fund more acquisitions. The move comes just ahead of the initial public offering in Hong Kong of Sinopharm's biggest competitor Shanghai Pharmaceutical Holdings Co. Ltd, and will add more heat to the consolidation war in China's distribution sector
Pfizer Looks To Team Up With Shanghai Pharmaceutical To Co-develop And Commercialize Pfizer Products In China
SHANGHAI - The world's largest pharmaceutical company Pfizer Inc. and China's second-largest distributor Shanghai Pharmaceutical Holdings Co. Ltd announced April 21 a memorandum of understanding to explore business opportunities, including the potential to jointly register, commercialize and distribute in China an innovative compound from Pfizer
Reading Into Pfizer's Changes: First Steps For New CEO
Pfizer Inc.'s new CEO Ian Read came out of the gates strong during the company's year-end financial presentation Feb. 1, with news that investors greeted warmly: additional, unexpected cuts to R&D and further R&D reorganization, a $5 billion share buyback program, and assurance that all options are on the table when it comes to Pfizer's diversified portfolio of businesses.